

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	1	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/718,846	10/718,846 11/21/2003		Rima Kaddurah-Daouk	AVZ-001CPUSCN	1479
959	7590	02/02/2005	EXAMINER		
LAHIVE &		FIELD, LLP.	CELSA, BENNETT M		
BOSTON, 1		09	ART UNIT	PAPER NUMBER	
•				1639	

DATE MAILED: 02/02/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/718,846	KADDURAH-DAOUK ET AL.				
Office Action Summary	Examiner	Art Unit				
	Bennett Celsa	1639				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) Responsive to communication(s) filed on	<b>_</b> ·					
2a) This action is <b>FINAL</b> . 2b) ⊠ This	action is non-final.					
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4) ⊠ Claim(s) 1-12 is/are pending in the application.  4a) Of the above claim(s) is/are withdrawn from consideration.  5) □ Claim(s) is/are allowed.  6) □ Claim(s) is/are rejected.  7) □ Claim(s) is/are objected to.  8) ⊠ Claim(s) 1-12 are subject to restriction and/or election requirement.						
Application Papers						
9) The specification is objected to by the Examine						
10)☐ The drawing(s) filed on is/are: a)☐ acce						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>						
Attachment(s)						
Notice of References Cited (PTO-892)     Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary Paper No(s)/Mail Da					
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date		ratent Application (PTO-152)				

### **DETAILED ACTION: Restriction/Election**

Claims 1-12 are currently pending.

#### Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - Claims 1-2 and 7-8, drawn to treating amylotropic lateral sclerosis, classified in class 514, subclass 565.
  - II. Claims 3-4 and 9-10, drawn to treating parkinsons disease, classified in class 514, subclass 565.
  - III. Claims 5-6 and 11-12, drawn to treating huntington's disease, classified in class 514, subclass 565.

The inventions are distinct, each from the other because of the following reasons: the above groups are drawn to independent and/or patentably inventive treatments of distinct "nervous system diseases". The different "nervous system diseases" (e.g. see specification page 9) as disclosed in the specification (and as presently claimed) are drawn to disease states which are unrelated in mechanism, have different etiologies, require different treatments and which further would require different and separately burdensome manual and/or computer bibliographic searches in both patent and literature databases.

2. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Application/Control Number: 10/718,846 Page 3

Art Unit: 1639

## Election of Species (Groups I-III above)

This application contains claims directed to methods of therapeutic use involving patetably distinct "creatinine compounds":

a. creatine;

b. creatine phosphate

which encompass compounds which differ in chemical structure and/or physicochemical properties which are capable of separate manufacture and/or use. Additionally, the search of these compounds in relation to any of the "nervous system diseases" would require different and separately burdensome manual and/or computer, structure and bibliographic searches in both patent and literature databases. Further, the individual "creatine compounds" are classifiable in different classes/subclasses. For example, creatine is classifiable in class 548, subclass 321.5, whereas creatinine phosphate is classifiable in class 558, subclass 70.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species from a. and b. above (e.g. a single specific compound) for prosecution on the merits.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Application/Control Number: 10/718,846 Page 4

Art Unit: 1639

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

1. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Art Unit: 1639

#### **Conclusion**

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bennett Celsa whose telephone number is 571-272-0807. The examiner can normally be reached on 8-5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Andrew Wang can be reached on 571-272-0811. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Bennett Celsa Primary Examiner Art Unit 1639

BC January 19, 2005